The biopharmaceutical industry should maintain its high standards for evidence and data, but should also be open to new pathways for evidence as interest in real-world evidence continues to grow, Aetion CEO Carolyn Magill writes in a recent article published on MedCity News.
Magill points to the Food and Drug Administration’s (FDA) recent efforts to better determine the effectiveness of RWE.
“The coming era of better, cost-effective outcomes for all patients requires biopharma to re-think its well-honed path to success,” she writes. “The FDA and other regulatory bodies around the world are signaling a new way forward.”
To read Magill’s full write up on MedCity News, click here.